Introduction

Multiple endocrine neoplasia type 1 (MEN1) syndrome is a very rare, inherited disorder characterized primarily by tumors of the anterior pituitary (15–90% of cases), parathyroid glands (95% of cases), and pancreatic tumors (30–80% of cases). This syndrome also includes the other rare neoplasms such as thymic, bronchial, and gastric carcinoids, meningiomas, adrenocortical and thyroid tumors, facial angiofibromas...
and collagenomas, visceral and cutaneous lipomas. Approximate prevalence of MEN1 syndrome is 1 in 35000 (1 in 20,000–1 in 40,000).\[^2\] It is a genetic disorder and runs in families with autosomal dominant trait. It is also known by name “Wermer syndrome” and occurs due to mutation of gene MEN1, which encodes Menin, a putative tumor suppressor.

Involvement of parathyroid may manifest with excess of serum calcium levels and rarely with renal calculi. Pancreas involvement may present in the form of islet cell tumor, which leads to excess production of gastrin, which in turn excess production of acid in stomach and leading to various symptoms such as pain abdomen, vomiting, diarrhea, gastrointestinal bleed, gastric and peptic ulcers, and perforations. Involvement of pituitary gland may manifest with tumors which produce excess of prolactin and growth hormones and manifests with various symptoms such as menstrual abnormalities, breast secretions, decreased sexual desire, erectile dysfunction, acromegaly, and gigantism. Diagnosis is made by proper family history, ultrasonography of the involved anatomical region, computed tomography (CT) scan, genetic tests, molecular imaging, and tumor markers/hormone levels of involved glands.\[^2\] There is no definitive treatment available for MEN1 syndrome per se treatment of MEN1 syndrome is done by surgical excision of the involved endocrine gland followed by hormone replacement. Gastroenteropancreatic neuroendocrine tumors (GEP-NET) are also manifested in association with MEN1 syndrome.

Cushing’s syndrome is described as a group of signs and symptoms due to excessive cortisol levels and also known as hypercortisolism.\[^3\] It can be due to exogenous or endogenous causes [Figure 1]. In majority of the cases, the cause is exogenous such as employment of external medications such as glucocorticoids such as hydrocortisone, prednisolone, and dexamethasone. Endogenous cause includes pituitary tumor that secrets excess amount of adrenocorticotropic hormone (ACTH), also known as Cushing’s disease as observed in our case. Cushing’s syndrome is manifested by group of symptoms such as moon facies, red cheeks, buffalo hump, truncal obesity, red striation over the abdomen, high blood pressure, poor wound healing, thin arms, headaches, rapid weight gain, and diabetes mellitus. Diagnosis is usually made by dexamethasone suppression test or a 24-h urinary measurement for cortisol, 24 h cortisol levels in saliva, CT scan, magnetic resonance imaging scan, and adrenal scintigraphy. Treatment is undertaken by gradual tapering of exogenous medication in most of the cases. Surgery is usually done for pituitary and adrenal adenomas and other incidentalomas. Medical management is tried with cortisol synthesis inhibitors (such as ketoconazole or metyrapone) in patients who are unwilling for surgery. Peptide receptor radionuclide therapy (PRRT) is a relatively new targeted therapeutic approach for patients, who harbor metastatic/inoperable NETs and can be given to those who express somatostatin receptor (SSTR) receptor at the tumor sites on SSTR-based imaging such as \[^{68}\text{Ga-DOTA-NOC/TATE}\) positron emission tomography (PET)-CT.\[^4\] We assessed therapy response to PRRT in this relatively rare group of patients harboring metastatic NETs in the setting of MEN1 syndrome and Cushing’s syndrome and present the profile and outcome of this treatment modality in this particular subgroup.

**Materials and Methods**

We performed a retrospective analysis of histopathologically proven NETs associated with MEN1 syndrome and Cushing’s syndrome from a population of patients who had undergone PRRT with \(^{177}\text{Lu-DOTATATE}\). The patients included in this study demonstrated histopathologically proven NET with raised serum chromogranin A and increased tracer uptake noted on initial diagnostic study (technetium \(^{99m}\text{Tc}\)-hydrazinonicotinamide [HYNIC]-tektrotyd [TOC]/\(^{68}\text{Ga-DOTA-NOC/TATE}\) PET-CT and fluorodeoxyglucose [FDG] PET-CT).

These patients were analyzed for response evaluation under three broad headings:
1. Symptomatically
2. Biochemically (tumor marker with serum chromogranin A) and
3. Scan (\(^{99m}\text{Tc-HYNIC-TOC}\) or \(^{68}\text{Ga-DOTA-NOC/TATE}\) PET-CT and fluorodeoxyglucose [FDG] PET-CT scan) wise.

Hematological and renal toxicity were evaluated using National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.0 score.
**Observations and Results**

On retrospective analysis of around 350 patients, we found five rare syndromic NET cases which included four MEN1 syndromes and one Cushing’s syndrome. Most of the cases had a family history and was initially asymptomatic with incidental finding of tumor on routine evaluation of nonspecific symptoms. In our series, the age ranged from 34 to 52 years (for MEN1 cases age ranges from 41 to 52) and had male predominance (male to female ratio of 3:2). The follow-up duration ranged from 7 to 26 months. The lesion site and its histopathological characterization, the details of PRRT administered (with its toxicity profile), the treatment response profile, and the dual tracer imaging features and its correlation with histopathology and prognosis are tabulated in Tables 1-4, respectively [Figures 2-8].

**Primary lesion site and its characteristics**

In most of the syndromic NET cases, the primary lesion was from GEP region followed by thymic region. Most of the MEN1 cases were found to have grade 1 well-differentiated NETs, which means MIB-1 index <2%. In the patient with Cushing’s syndrome, the primary lesion involved thymus with histopathology as thymic carcinoma with neuroendocrine differentiation. These characteristics are tabulated in Table 1.

**Cumulative dose and toxicity**

In most MEN1 cases, there was no specific toxicity noted to PRRT and overall well tolerated with the

| Patient number | Histopathological characterization | Lesion site |
|----------------|-----------------------------------|-------------|
| Case 1 (MEN1)  | Well-differentiated NET (mediastinum), atypical carcinoid of thymus, NET pancreas | NET of thymus and pancreas |
| Case 2 (MEN1)  | Duodenal NET with gastric carcinoids Type II (MIB-1: <2%) | Duodenal NET with gastric carcinoids |
| Case 3 (MEN1)  | Well-differentiated NET of pancreas, Grade I (MIB-1: 1-2%) | Pancreatic NET with liver metastases |
| Case 4 (MEN1)  | Well-differentiated NET, Grade I (MIB-1: <1%) | NET of pancreas with liver metastases and stomach lymph nodes involvement |
| Case 5 (Cushing’s syndrome) | Thymic carcinoma with neuroendocrine differentiation | Thymus with adrenocorticotropic hormone-dependent Cushing’s syndrome |

**Table 2: Number of cycles of peptide receptor radionuclide therapy with $^{177}$Lu-DOTA-octreotate therapy administered and toxicity profile on follow-up**

| Patient number | Number cycles of peptide receptor radionuclide therapy (cumulative dose) (MBq) | Follow-up duration (months) | Toxicity profile (hematological/renal/others) |
|----------------|---------------------------------------------------------------------------------|-----------------------------|---------------------------------------------|
| Case 1         | 5 cycles (31,561)                                                               | 26                          | Nil                                         |
| Case 2         | 2 cycles (11,100)                                                                | 10                          | Nil                                         |
| Case 3         | 3 cycles (18,648)                                                                | 51                          | Nil                                         |
| Case 4         | 2 cycles (11,618)                                                                | 7                           | Nil                                         |
| Case 5         | 3 cycles (18,685)                                                                | 10                          | Mild toxicity noted hematological (platelet count 1.89→1.56 lakh/cmm)/renal (total glomerular filtration rate 67→57 ml/min) |

**Table 3: Treatment response assessment**

| Patient number | Symptomatic | Biochemical | Scan response |
|----------------|-------------|-------------|---------------|
| Case 1         | Initially presented with headache and now asymptomatic | Serum CgA decreased (631.5→16.8 ng/ml) | HYNIC TOC/Go DOTA; Decreased in intensity FDG PET; Reduced (low-grade uptake initially) |
| Case 2         | 100% improvement in pain abdomen | Serum CgA reduced significantly (57,244→1.5 ng/ml) | HYNIC TOC/Go DOTA; Decreased intensity FDG PET; FDG avid peripancreatic node completely resolved |
| Case 3         | ~100% improvement in pain abdomen | Serum CgA increased (2645→9230 ng/ml) | HYNIC TOC/Go DOTA; Similar FDG PET; Similar |
| Case 4         | 100% resolution of pain abdomen | Serum CgA reduced (695→593 ng/ml) | HYNIC TOC/Go DOTA; Decreased intensity FDG PET; Decreased intensity |
| Case 5         | Initially decreased followed by flare of symptoms | Serum CgA reduced (511.7→53.3 ng/ml) | HYNIC TOC/Go DOTA; Increased in intensity and new lesion is noted FDG PET; Increased in intensity and new lesion is noted |

HYNIC: Hydrazinonicotinamide; PET: Positron emission tomography; FDG: Fluorodeoxyglucose; TOC: Tektrotyd; CgA: Chromogranin A
cumulative activity administered till date without any significant side effects. In Cushing’s syndrome case, there was a mild hematological and renal toxicity noted; and that toxicity could have been accentuated with other modes of treatment such as chemotherapy and radiotherapy which were tried earlier in the case. The cumulative dose administered and toxicity profile in each case studied in this series is tabulated in Table 2.

Treatment response assessment
Response assessment was done by three parameters (1) symptomatically (2) Biochemically (tumor marker: Serum chromogranin A) and (3) Scan assessment ($^{99m}$Tc HYNIC TOC or $^{68}$Ga-DOTA-NOC/TATE PET-CT and FDG PET-CT scan).

Scan-wise, in most of the MEN1 cases, there was partial response observed (75%; three out of four MEN2 cases) and one case showed stable disease (25%). There was a disease progression noted in Cushing’s syndrome case with initial phase of partial response followed by new lesions observed during follow-up period.

The details of response assessment are tabulated in Table 3. Overall, there was a partial response noted in 60% of the syndromic NET cases and stable disease observed in 20% and disease progression in 20%.

### Table 4: Dual tracer imaging features: Relevance to prognosis

| Patient | Selective serotonin reuptake inhibitor | FDG | Outcome |
|---------|----------------------------------------|-----|---------|
| Case 1  | Base line: Thymus (SUVmax - 20.43) and pancreatic mass (55.94) Follow-up: Thymus (SUVmax - 4.58) and pancreatic mass (15.72) | Baseline: Low-grade thymic lesion (2.75) Follow-up: Resolved completely | Symptomatic: Good response Biochemical: Good response Scan: HYNIC TOC/Ga DOTA - partial response; FDG PET- good response |
| Case 2  | Baseline: Multiple gastric polyps (SUVmax - 28.83) and peripancreatic node (22.9) Follow-up: Multiple gastric polyps (SUVmax - 12.71) and peripancreatic nodes resolved completely | Baseline: Peripancreatic node (SUVmax 6.5) Follow-up: Resolved completely | Symptomatic: Good response Biochemical: Good response Scan: HYNIC TOC/Ga DOTA - partial response; FDG PET- good response |
| Case 3  | Baseline (Ga-DOTA): Pancreatic tail lesion, multiple liver lesions, peripancreatic and aortocaval node. Follow-up (HYNIC TOC): Multiple liver lesions | Baseline: Precarinal node (SUVmax 7.7), multiple liver lesions-largest (SUVmax 12.6), pancreatic mass (SUVmax 12.6) Follow-up: Precarinal node resolved completely, multiple liver lesions-largest (SUVmax 24.15), pancreatic mass (SUVmax 16.4) | Symptomatic: Good response Biochemical: Progression Scan: HYNIC TOC/Ga DOTA- partial; FDG PET- partial |
| Case 4  | Baseline: Breast lesion (SUVmax - 6.40), liver (SUVmax - 13.64), pancreatic mass (SUVmax - 36.51), paraaortic node (11.35) Follow-up: Breast lesion (SUVmax - 4.17), liver (SUVmax - 9.37), pancreatic mass (SUVmax - 9.65), paraaortic node (11.94) | Baseline: Breast lesion (SUVmax 3.60), stomach wall (8.46) Follow-up: Breast lesion (SUVmax 3.01), stomach wall (SUVmax 6.17) | Symptomatic: Good response Biochemical: Partial response Scan: HYNIC TOC/Ga DOTA - partial response; FDG PET-partial response |
| Case 5  | Baseline: Paraaortic nodes (SUVmax - 4.69), orbit (SUVmax - 7.10), anterior mediastinum (SUVmax - 6.46) Follow-up: Paraaortic nodes (SUVmax - 5.46), orbit (SUVmax - 8.3), anterior mediastinum (SUVmax - 5.63) and new lesions in left ilium and left lung | Increased in intensity with new lesions (exact report not available in our system) | Symptomatic: Progression Biochemical: Good response Scan: HYNIC TOC/Ga DOTA-progression at 10 months; FDG PET-progression |

HYNIC: Hydrazinonicotinamide; PET: Positron emission tomography; FDG: Fluorodeoxyglucose; SUVmax: Maximum standardized uptake value; TOC: Tektrotyd
Cushing’s syndrome due to thymic carcinoma with neuroendocrine differentiation involving multiple organs.

The first case presented with pituitary adenoma and 10 years later was diagnosed to have parathyroid tumor. Subsequently, mediastinal mass pathology was suggestive of neuroendocrine carcinoma with increased SSTR expression on $^{68}$Ga-DOTATATE scan. He responded well to 5 cycles of PRRT, showing symptomatic, biochemical, and $^{68}$Ga-DOTA/HYNIC TOC and $^{18}$F-FDG PET-CT scan response.

The second case was a diagnosed case of MEN1 syndrome found to have SSTR expression on $^{68}$Ga-DOTATATE PET-CT scan in thickened proximal two-third of stomach, the first part of duodenum, peripancreatic lymph node. The patient was treated with 2 cycles of $^{177}$Lu-DOTATATE therapy and good symptomatic, biochemical, and scan response without any toxicity.

The third case presented with pain abdomen and had a previous history of pituitary adenoma. Subsequently, he was diagnosed as pancreatic NET with liver and multiple abdominal metastases, for which patient was treated with 3 cycles of $^{177}$Lu-DOTATATE. The patient responded well symptomatically and had stable disease scan wise, but there was increase in tumor marker which was likely due to intake of proton pump inhibitor during serum chromogranin A estimation. Till date, the patient is asymptomatic with stable disease.

The fourth case also presented with chronic recurrent pain abdomen, initially diagnosed as Zollinger-Ellison
syndrome and 6 years later diagnosed as pancreatic NET and medically managed. Now, after 10 years of initial presentation, she received 2 cycles $^{177}$Lu-DOTATATE therapy, following which patient shown significant symptomatic, biochemical, and scan response.

The 5th case was a known case of ACTH-dependent Cushing’s syndrome, postsurgery, postradiotherapy, and chemotherapy with progressive disease received 3 cycles of $^{177}$Lu-DOTATATE therapy. Initially, the patient responded clinically with reduced levels of tumor marker but later, symptoms reappeared and scan showing progressive disease with mild hematological/renal toxicity.

Dual tracer imaging with $^{68}$Ga-DOTATATE PET-CT and $^{18}$F-FDG PET-CT have a significant role in treatment selection and disease prognosis.[4] Well-differentiated NET with somatostatin expression in the primary lesion as well as metastatic lesions greater than physiological hepatic tracer uptake is a prerequisite for PRRT.[5,6] FDG uptake in primary and metastatic lesions has been equated with metabolic aggressiveness of the tumor and which is more observed in poorly differentiated NET.[7] An inverse relation is also reported with
FDG and DOTATATE with aggressiveness/differentiation of tumor (i.e., well-differentiated tumor showing somatostatin expression with nil/low FDG expression, whereas poorly differentiated tumor shows poor somatostatin expression with high FDG expression). In the present case series, this feature was clearly observed as the cases were of well-differentiated NET with low FDG uptake. On follow-up studies, the FDG uptake reduced earlier than SSTR-based imaging, suggesting the change in FDG uptake to be an important parameter in the treatment evaluation of NETs.

**Conclusion**

The present retrospective evaluation in our case series showed an overall good response either decrease in metabolic aggressiveness of lesions or stabilization of disease process to PRRT in NETs in association with MEN1 syndrome. There was also good symptomatic and biochemical improvement without any hematological/renal toxicity. Thus, prolongation of symptom-free survival can be expected with 177Lu-DOTATATE therapy in these patients. The fifth case which was a resistant ACTH-dependent tumor presented in the late stage and PRRT could not halt the disease process. Thus, we can conclude that 177Lu-DOTATATE therapy for NETs in association with MEN1 syndrome has a significant role in disease stabilization and good symptomatic response with better health-related quality of life.

**References**

1. Marini F, Falchetti A, Luzi E, Tonelli F, Maria Luisa B. Multiple Endocrine Neoplasia Type 1 (MEN1) Syndrome. In: Riegert-Johnson DL, Boardman LA, Hefferon T, Roberts M, editors. Cancer Syndromes [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2009. Accessible from: http://www.ncbi.nlm.nih.gov/pubmed/21249756. [Last updated on 2008 Aug 09].

2. Jiang L, Schipper ML, Li P, Cheng Z. 123I labeled metaiodobenzylguanidine for diagnosis of neuroendocrine tumors. Rep Med Imaging 2009;2:79‑89.

3. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet 2006;367:1605‑17.

4. Basu S, Sirohi B, Shrikhande SV. Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: Its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT. Eur J Nucl Med Mol Imaging 2014;41:1492‑6.

5. Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 1999;10 Suppl 2:S23‑9.

6. Kwekkeboom DJ, Krenning EP, Lebthah R, Komminoth P, Kos-Kudla B, de Herder WW, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 2009;90:220‑6.

7. Kwee TC, Basu S, Saboury B, Ambrosini V, Torigian DA, Alavi A. A new dimension of FDG-PET interpretation: Assessment of tumor biology. Eur J Nucl Med Mol Imaging 2011;38:1158‑70.